Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 403

1.
2.
3.

Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.

Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.

J Clin Psychopharmacol. 2009 Jun;29(3):239-47. doi: 10.1097/JCP.0b013e3181a390ce.

PMID:
19440077
5.

Long-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate.

Ginsberg Y, Hirvikoski T, Grann M, Lindefors N.

Eur Arch Psychiatry Clin Neurosci. 2012 Dec;262(8):705-24. doi: 10.1007/s00406-012-0317-8. Epub 2012 Apr 21.

6.

Long-Term Treatment Outcome in Adult Male Prisoners With Attention-Deficit/Hyperactivity Disorder: Three-Year Naturalistic Follow-Up of a 52-Week Methylphenidate Trial.

Ginsberg Y, Långström N, Larsson H, Lindefors N.

J Clin Psychopharmacol. 2015 Oct;35(5):535-43. doi: 10.1097/JCP.0000000000000395.

PMID:
26284932
7.

Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.

Chronis-Tuscano A, Seymour KE, Stein MA, Jones HA, Jiles CD, Rooney ME, Conlon CJ, Efron LA, Wagner SA, Pian J, Robb AS.

J Clin Psychiatry. 2008 Dec;69(12):1938-47. Epub 2008 Dec 2.

PMID:
19192455
8.

A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder.

Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, Pratt RD.

J Clin Psychiatry. 2008 Jan;69(1):149-59. Erratum in: J Clin Psychiatry. 2008 Feb;69(2):329.

PMID:
18312050
9.

Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate.

Buitelaar JK, Kooij JJ, Ramos-Quiroga JA, Dejonckheere J, Casas M, van Oene JC, Schäuble B, Trott GE.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):554-60. doi: 10.1016/j.pnpbp.2010.12.016. Epub 2010 Dec 23.

PMID:
21185347
10.

Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.

Jain U, Hechtman L, Weiss M, Ahmed TS, Reiz JL, Donnelly GA, Harsanyi Z, Darke AC.

J Clin Psychiatry. 2007 Feb;68(2):268-77.

PMID:
17335326
12.

A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.

Greenhill LL, Findling RL, Swanson JM; ADHD Study Group.

Pediatrics. 2002 Mar;109(3):E39.

PMID:
11875167
13.

Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.

Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM.

Arch Pediatr Adolesc Med. 2006 Jan;160(1):82-90.

PMID:
16389216
14.

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, Lee E, Buitelaar JK.

Biol Psychiatry. 2008 May 15;63(10):981-9. doi: 10.1016/j.biopsych.2007.11.008. Epub 2008 Jan 22.

PMID:
18206857
15.

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.

Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G.

Pediatrics. 2001 Oct;108(4):883-92.

PMID:
11581440
16.

A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.

Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK.

J Am Acad Child Adolesc Psychiatry. 2004 Nov;43(11):1406-14.

PMID:
15502600
17.

Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate.

Buitelaar JK, Casas M, Philipsen A, Kooij JJ, Ramos-Quiroga JA, Dejonckheere J, van Oene JC, Schäuble B.

Psychol Med. 2012 Jan;42(1):195-204. doi: 10.1017/S0033291711000845. Epub 2011 Jun 1.

18.

Personality disorders in ADHD Part 2: The effect of symptoms of personality disorder on response to treatment with OROS methylphenidate in adults with ADHD.

Robison RJ, Reimherr FW, Gale PD, Marchant BK, Williams ED, Soni P, Halls C, Strong RE.

Ann Clin Psychiatry. 2010 May;22(2):94-102.

PMID:
20445836
19.

Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.

Research Units on Pediatric Psychopharmacology Autism Network.

Arch Gen Psychiatry. 2005 Nov;62(11):1266-74.

PMID:
16275814
20.

Is response to OROS-methylphenidate treatment moderated by treatment with antidepressants or psychiatric comorbidity? A secondary analysis from a large randomized double blind study of adults with ADHD.

Biederman J, Mick E, Spencer T, Surman C, Faraone SV.

CNS Neurosci Ther. 2012 Feb;18(2):126-32. doi: 10.1111/j.1755-5949.2010.00233.x. Epub 2011 Aug 5.

PMID:
22070421

Supplemental Content

Support Center